Product information and disease descriptionPlace of product in therapyApproaches to treatment
Care management intervention strategies
5 evidence topics · 3 sources
US HAEA Medical Advisory Board guidelines: on-demand medication access
On-demand treatment during long-term prophylaxis: guideline recommendations
“We recommend that patients have access to ODT, even while receiving LTP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that patients or their caregivers are advised to always carry enough medication to treat at least 2 HAE attacks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Self-administration and home therapy
“Self-administration and home therapy are available for all C1-INH products, icatibant, berotralstat, sebetralstat, donidalorsen, garadacimab, and lanadelumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that patients and their caregivers be educated in how to administer ODT, including self-administration with all available formulations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring of disease control with validated instruments
“We recommend that all patients with HAE use validated instruments to assess disease activity, severity, disease control, treatment efficacy, and QoL, and that they undergo regular reassessments to ensure optimal therapeutic management.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend evaluating efficacy and safety of the long‐term prophylactic agent in pediatric patients with hereditary angioedema due to C1 inhibitor deficiency at least three and six months after initiation, then at least annually.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote